Search clinical trials for: MK-8189

Total 1766 results

Organon and Co

Completed

Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)

Hypogonadotropic Hypogonadism

Brazil, Denmark, Italy, Mexico, Russian Federation, South Africa
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

Renal Cell Carcinoma
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(MK-3475-199/KEYNOTE-199)

Metastatic Castration-resistant Prostate Cancer
Hoosier Cancer Research Network
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab in Combination With Chemotherapy for Patients With Advanced Colorectal Cancer

Colorectal Cancer

United States
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001) (KEYNOTE-001)

Cancer, Solid Tumor
Aduro Biotech, Inc.
Merck Sharp & Dohme LLC

Terminated

Safety and Efficacy of CRS-207 With Pembrolizumab in Gastric, Gastroesophageal Junction or Esophageal Cancers

Gastric Adenocarcinoma | Esophageal Adenocarcinoma | Gastroesophageal Junction Adenocarcinoma

United States
Merck Sharp & Dohme LLC

Completed

A Bridging Trial Comparing Sugammadex (Org 25969) at 1-2 Post-Tetanic Count (PTC) in Caucasian Participants. Part B (P05974)

Anesthesia, General
Shaheen Alanee
Merck Sharp & Dohme LLC

Unknown

Pembrolizumab in Combination With BCG After Ablation in Patients With UUTTCC Without Nephroureterectomy

Endoscopic Surgical Procedure | High Risk Superficial Upper Urinary Tract Transitional Cell Carcinoma | Transitional Epithelial Cells

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)

Malignant Melanoma

United States, Australia, Austria, Brazil, Canada, Chile, China, France, Germany, Israel, Italy, Korea, Republic of, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)

Urothelial Carcinoma

Hungary, United States, Argentina, Australia, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, Turkey, United Kingdom
Merck Sharp & Dohme LLC

Completed

An Efficacy and Safety Study of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in the Treatment of Chronic Hepatitis C Virus (HCV) Genotype (GT)1, 4, or 6 Infection in Treatment-Naïve Participants Who Are on Opiate Substitution Therapy (MK-5172-062) (C-EDGE CO-STAR)

Chronic Hepatitis C
Peloton Therapeutics, Inc., a subsidiary of Merck...

Active, not recruiting

A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)

VHL - Von Hippel-Lindau Syndrome | VHL Gene Mutation | VHL Syndrome | VHL Gene Inactivation | VHL-Associated Renal Cell Carcinoma | VHL-Associated Clear Cell Renal Cell Carcinoma

United States, Denmark, United Kingdom, France
Merck Sharp & Dohme LLC

Completed

Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-052)

Urothelial Cancer
Merck Sharp & Dohme LLC

Completed

Study of MK-3475 (Pembrolizumab) in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma After Treatment With Platinum-based and Cetuximab Therapy (MK-3475-055/KEYNOTE-055)

Head and Neck Squamous Cell Carcinoma
Eli Lilly and Company

Completed

A Study of LY3819253 (LY-CoV555) in Healthy Participants

Healthy

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma

UC (Urothelial Cancer)

United States, Spain, Hungary, Israel, United Kingdom, Korea, Republic of, Taiwan, Denmark, France, Netherlands, Italy, Canada, Japan, Turkey, Germany, Ireland, Australia, Russian Federation
Yale University

Completed

MK-3475 in Melanoma and NSCLC Patients With Brain Metastases

Melanoma | Non-Small Cell Lung Cancer | Brain Metastases

United States
Merck Sharp & Dohme LLC

Terminated

Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161)

Advanced Melanoma

United States
Georgetown University
Merck Sharp & Dohme LLC; Incyte Corporation

Unknown

Pembrolizumab and Epacadostat in Patients With Thymic Carcinoma

Thymic Carcinoma | Thymus Neoplasms | Thymus Cancer

United States
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

Insomnia

Netherlands
Merck Sharp & Dohme LLC

Recruiting

Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010)

Solid Tumor | Endometrial Cancer | Cutaneous Squamous Cell Carcinoma

Canada, Australia, Taiwan, Italy, Malaysia, United States, Netherlands, Turkey, France, Germany
Merck Sharp & Dohme LLC
Eisai Inc.

Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study (LEAP-007)

Non-small Cell Lung Cancer

China
Merck Sharp & Dohme LLC

Completed

A Study of MK-7145 Compared to Placebo and Hydrochlorothiazide for Lowering Blood Pressure in Male Participants With Hypertension (MK-7145-009)

Hypertension
Merck Sharp & Dohme LLC

Active, not recruiting

KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C/KEYMAKER-U01C)

Carcinoma, Non-Small-Cell Lung

Poland, United States, Hungary, Israel, Italy, Korea, Republic of, Spain
NuGenerex Immuno-Oncology
Merck Sharp & Dohme LLC; NSABP Foundation Inc

Active, not recruiting

Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast Cancer (NSABP FB-14)

Triple-negative Breast Cancer

United States
Afferent Pharmaceuticals, Inc.

Terminated

The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Participants With Interstitial Cystitis /Bladder Pain Syndrome (MK-7264-005)

Bladder Pain Syndrome

United States
Pancreatic Cancer Research Team
Merck Sharp & Dohme LLC; University of Washington; Halozyme Therapeutics

Unknown

Second-line Study of PEGPH20 and Pembro for HA High Metastatic PDAC

Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma

United States
ALK-Abelló A/S

Completed

Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (Study P05233)(COMPLETED)

Conjunctivitis | Rhinitis; Allergic, With Asthma
Merck Sharp & Dohme LLC
Ariad Pharmaceuticals

Completed

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Sarcoma, Soft Tissue | Osteosarcoma | Leiomyosarcoma | Liposarcoma | Metastases
Amunix, a Sanofi Company
Merck Sharp & Dohme LLC

Recruiting

To Access the Safety and Effects of Intravenous Administration of AMX-818 Alone and in Combination With Pembrolizumab in Adult Participants With Locally Advanced or Metastatic HER2-Expressing Cancers

Locally Advanced or Metastatic HER2-Expressing Cancers

Australia, Spain, France, Portugal
Craig L Slingluff, Jr

Recruiting

Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer (UVA-PC-PD101)

Pancreatic Cancer

United States
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)

Lung Cancer

Spain, Ireland, Canada, Denmark, Japan, Israel, Korea, Republic of, Malaysia, United States, Turkey, Italy, Ukraine, Switzerland, Russian Federation, Poland, Australia, Estonia, United Kingdom
Incyte Corporation
Merck Sharp & Dohme LLC

Completed

Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307)

UC (Urothelial Cancer)

United States, France, Belgium, Israel, Spain, United Kingdom, Korea, Republic of, Taiwan, Australia, Netherlands, Japan, Germany, Ukraine, Canada, Ireland, Italy, Poland, Russian Federation
Merck Sharp & Dohme LLC

Terminated

MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049)

Migraine
Merck Sharp & Dohme LLC
Duke Clinical Research Institute

Terminated

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P04736)

Myocardial Infarction | Myocardial Ischemia | Atherosclerosis
Mark Pomerantz, MD
Merck Sharp & Dohme LLC; Rainier Therapeutics

Terminated

Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract

Bladder Cancer

United States
Merck Sharp & Dohme LLC

Completed

MK-0524B Lipid Study (MK-0524B-063)

Mixed Dyslipidemia | Primary Hypercholesterolemia
Maastricht University Medical Center

Unknown

Vitamin K2 Effect on Vascular Stiffening in Subjects With a Poor Vitamin K-status

Vascular Stiffness
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Merck Sharp & Dohme LLC
Eisai Inc.

Active, not recruiting

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Carcinoma, Hepatocellular

Colombia, Israel, Taiwan, United States, Australia, Brazil, Chile, China, Denmark, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, New Zealand, Norway, Portugal, Puerto Rico, Spain, Thailand, Turke... and more
EyePoint Pharmaceuticals, Inc.

Completed

Utilization and Safety of the Mk II Inserter and the Safety of the FAI Insert in Non-Infectious Uveitis (MkII)

Non-Infectious Uveitis

United States
Emory University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Recruiting

Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy

Plasma Cell Myeloma

United States
Royal Marsden NHS Foundation Trust
Merck Sharp & Dohme LLC; Institute of Cancer Research, United Kingdom; National...

Recruiting

Pembrolizumab in Muscle Invasive/Metastatic Bladder Cancer (PLUMMB)

Invasive Bladder Cancer

United Kingdom
Merck Sharp & Dohme LLC

Completed

A Study to Evaluate Molnupiravir (MK-4482) in Participants With Moderate Hepatic Impairment (MK-4482-016)

Hepatic Impairment

United States
Indonesia University

Active, not recruiting

Comparison of Quality of Life in Moderate Acne Vulgaris Patients Based on Acne-QoL-INA Using Standard Therapy With and Without Acne Lesions Extraction

Quality of Life | Acne Vulgaris

Indonesia
AbbVie
Merck Sharp & Dohme LLC

Terminated

A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Cancer - Acute Myeloid Leukemia

United States, Australia, Spain
Lawrence Feldman, MD
Merck Sharp & Dohme LLC; HiberCell, Inc.

Active, not recruiting

Pembrolizumab + Imprime PGG for Metastatic Non-small Cell Lung Cancer After Progression on First-Line Therapy: Big Ten Cancer Research Consortium BTCRC-LUN15-017

Non-Small Cell Lung Cancer

United States
Lawson Health Research Institute

Active, not recruiting

Histidine Therapy: A Project to Treat HARS Deficiency

HARS Syndrome

Canada
Southern Illinois University
Merck Sharp & Dohme LLC

Active, not recruiting

MK-3475/BCG in High Risk Superficial Bladder Cancer (MARC)

Bladder Cancer

United States
Afferent Pharmaceuticals, Inc.

Completed

A 12-Week Study in Participants With Refractory Chronic Cough (MK-7264-012)

Refractory Chronic Cough

3

Subscribe